Brief: Repare Therapeutics Presents Updated Clinical Data From Ongoing Phase 1/2 TRESR Study Of RP-3500 Monotherapy In Solid Tumors
11/04/2022 21:33
April 11 (Reuters) - Repare Therapeutics Inc RPTX.O :
* REPARE THERAPEUTICS PRESENTS UPDATED CLINICAL DATA FROM
THE
ONGOING PHASE 1/2 TRESR STUDY OF RP-3500 MONOTHERAPY IN SOLID
TUMORS AT THE 2022 AACR ANNUAL MEETING
* REPARE THERAPEUTICS INC - RP-3500 SHOWS ROBUST ACTIVITY IN
OVARIAN CANCER DEMONSTRATING 75% CBR, WITH 25% ORR AND MPFS OF
35 WEEKS
* REPARE THERAPEUTICS - UPDATED MONOTHERAPY RESULTS SHOW 43%
CBR
IN SOLID TUMORS ACROSS GENOTYPES, AND POTENTIAL BEST-IN-CLASS
SAFETY AND TOLERABILITY
Source text for Eikon: ID:nBw8dKKBka
Further company coverage: RPTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Repare Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Brief: Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal
Repare Therapeutics Q2 net loss narrows to $16.7 mln